Publicaciones en colaboración con investigadoras/es de Hospital de Cruces (18)

2024

  1. CircRNAome of Childhood Acute Lymphoblastic Leukemia: Deciphering Subtype-Specific Expression Profiles and Involvement in TCF3::PBX1 ALL

    International Journal of Molecular Sciences, Vol. 25, Núm. 3

2023

  1. microRNA sequencing for biomarker detection in the diagnosis, classification and prognosis of Diffuse Large B Cell Lymphoma

    Scientific reports, Vol. 13, Núm. 1, pp. 12159

2020

  1. Role of rs10406069 in miR-5196 in hyperdiploid childhood acute lymphoblastic leukemia

    Epigenomics, Vol. 12, Núm. 22, pp. 1949-1955

  2. Variability in Cerebrospinal Fluid MicroRNAs Through Life

    Molecular Neurobiology, Vol. 57, Núm. 10, pp. 4134-4142

2019

  1. An update on the implication of physical activity on semen quality: a systematic review and meta-analysis

    Archives of Gynecology and Obstetrics, Vol. 299, Núm. 4, pp. 901-921

  2. Cell-free DNA as a biomarker in diffuse large B-cell lymphoma: A systematic review

    Critical Reviews in Oncology/Hematology, Vol. 139, pp. 7-15

  3. Impact of physical activity on semen quality among men from infertile couples

    European Journal of Obstetrics and Gynecology and Reproductive Biology, Vol. 237, pp. 170-174

  4. MiRNA deregulation in childhood acute lymphoblastic leukemia: A systematic review

    Epigenomics, Vol. 12, Núm. 1, pp. 69-80

2018

  1. Circulating miRNAs as biomarkers in diffuse large B-cell lymphoma: A systematic review

    Oncotarget, Vol. 9, Núm. 32, pp. 22850-22861

  2. Involvement of miRNA polymorphism in mucositis development in childhood acute lymphoblastic leukemia treatment

    Pharmacogenomics, Vol. 19, Núm. 18, pp. 1403-1412

2016

  1. Lack of association of the CEP72 RS924607 TT genotype with vincristine-related peripheral neuropathy during the early phase of pediatric acute lymphoblastic leukemia treatment in a Spanish population

    Pharmacogenetics and Genomics, Vol. 26, Núm. 2, pp. 100-102

  2. Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia

    Pharmacogenomics, Vol. 17, Núm. 7, pp. 731-741

2014

  1. Errors in the interpretation of copy number variations due to the use of public databases as a reference

    Cancer Genetics, Vol. 207, Núm. 4, pp. 164-167

  2. Methylation of the nonhomologous end joining repair pathway genes does not explain the increase of translocations with aging

    Age, Vol. 36, Núm. 6

  3. Noncoding RNA-related polymorphisms in pediatric acute lymphoblastic leukemia susceptibility

    Pediatric Research, Vol. 75, Núm. 6, pp. 767-773

  4. Pharmacogenetics of MicroRNAs and MicroRNAs biogenesis machinery in pediatric acute lymphoblastic leukemia

    PLoS ONE, Vol. 9, Núm. 3

2013

  1. Polymorphisms in the methotrexate transport pathway: A new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia

    Pharmacogenetics and Genomics, Vol. 23, Núm. 2, pp. 53-61

2011

  1. Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia

    Pediatric Blood and Cancer, Vol. 57, Núm. 4, pp. 612-619